Prosomnus (OSA)

Executive Summary

Prosomnus Sleep Technologies is a medical device company dedicated to providing patient-friendly alternatives to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) and snoring. Founded in 2013 and headquartered in Pleasanton, California, the company designs and commercializes custom-fitted precision oral appliances that reposition the jaw to maintain airway patency during sleep. These devices are less intrusive and more comfortable than CPAP masks, addressing key compliance issues that have historically limited the effectiveness of sleep apnea treatments. With coverage by most medical insurance plans, Prosomnus’s products are positioned to capture a significant share of the estimated $8 billion global sleep apnea device market, particularly among the 40% of OSA patients who cannot tolerate CPAP. The company’s strategic focus on innovation and patient-centric design has yielded a growing portfolio of FDA-cleared appliances, including the proprietary PRO and EVO series. As awareness of untreated sleep apnea’s links to cardiovascular disease, stroke, and diabetes increases, Prosomnus is poised to benefit from expanding diagnosis rates and a shift toward personalized therapy. Recent initiatives include expanding direct-to-consumer marketing and forging partnerships with sleep clinics to streamline patient access. With a scalable manufacturing platform and a seasoned management team, Prosomnus is well-positioned to drive growth in the high-demand oral appliance segment.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance of Next-Generation PRO X Device75% success
• Q4 2026Positive 12-Month Clinical Study Results on EVO Series60% success
• Q2 2026Major Insurance Coverage Expansion Agreement55% success